Johnson & Johnson at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Johnson & Johnson takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1029. Its program centres on non-small cell lung cancer with EGFR mutations, with a focus on precision treatment shared across the care team. It also covers personalising treatment for genitourinary cancers while preserving quality of life.
| Organization | ESMO 2026 Attendance |
|---|---|
Healthcare company whose Innovative Medicine business markets oncology drugs including amivantamab, daratumumab and teclistamab. | Booth Exhibiting at Booth 1029 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 14:00–15:30 J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers |
Instantly find 20 buyers from Johnson & Johnson
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction